Navigation Links
DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
Date:9/19/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 19, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma" or "DelMar") today announced a discussion on CEOLIVE.TV by Jeffrey Bacha, president and CEO of DelMar Pharma, a cancer-focused company developing new therapies for patients with little to no treatment options. DelMar's first drug in development is VAL-083, a potential first-in-class treatment for glioblastoma multiforme (GBM). 

Mr. Bacha will also discuss how the company is strategically advancing VAL-083 in the U.S., where the drug is in encouraging Phase I/II clinical trials for glioblastoma, and in China, where the drug is currently approved to treat lung cancer and chronic myelogenous leukemia (CML).

Watch the interview here: http://www.ceolive.tv/delmarpharma

Quotes:

Jeffrey Bacha, president and CEO of DelMar Pharma, "We are testing VAL-083 in glioblastoma, where there is the greatest need and greatest potential impact, and we are running our studies as quickly as possible to get this promising drug into the hands of physicians to treat the patients who need it the most."

Key Facts:

  • More than 15,000 people are diagnosed with glioblastoma each year in the U.S.
  • Approximately half of glioblastoma patients will fail the approved therapies
  • Many patients develop resistance to the front-line therapy, Temodar® ($950 million annual sales), because of an enzyme known as MGMT
  • VAL-083 acts through a mechanism independent of MGMT
  • Interim clinical trial results presented at ASCO suggest VAL-083 may have an improved s
    '/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/rt3mhz/deciphering ... "Deciphering Global Major Pharmaceutical Companies, New Outsourcing Demands ... It has been publicly recognized that global ... series of challenges in the recent years. The ... in small molecule product manufacturing; increasingly challenging process ...
(Date:7/7/2015)... 7, 2015   Decision Resources Group ... dialysis patient management in the U.S. versus the ... U.S. and EU5 nephrologists from approximately 1,870 dialysis ... the most commonly used renal medications in dialysis ... considerably between the two regions.      Other ...
(Date:7/7/2015)... BANGALORE , July 7, 2015 ... innovative clinical trial data management solutions, has been featured ... publication named " EDC and eCOA / ePRO Market ... is one of the leading providers of research and ... 22 EDC and eCOA / ePRO tools in the ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
... Inc. (Nasdaq: STRM ) today announced financial ... ended January 31, 2011. Highlights for the ... purchase contracts for add-on licenses with existing clients totaling ... recognized during the quarter; Company completed and ...
... N.J., April 12, 2011 Novartis Pharmaceuticals Corporation ... Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... treatment of patients with advanced neuroendocrine tumors (NET) ... provided after presentation of data from the everolimus ...
Cached Medicine Technology:Streamline Health® Solutions Reports Q4 Results 2Streamline Health® Solutions Reports Q4 Results 3Streamline Health® Solutions Reports Q4 Results 4Streamline Health® Solutions Reports Q4 Results 5Streamline Health® Solutions Reports Q4 Results 6Streamline Health® Solutions Reports Q4 Results 7Streamline Health® Solutions Reports Q4 Results 8Streamline Health® Solutions Reports Q4 Results 9Streamline Health® Solutions Reports Q4 Results 10Streamline Health® Solutions Reports Q4 Results 11Streamline Health® Solutions Reports Q4 Results 12Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
(Date:7/7/2015)... ... 07, 2015 , ... WiseWear®, a wearable startup that specializes ... of luxury smart jewelry called the Socialite™ collection. The product line is available ... , “The Socialite collection was crafted to inspire women to be safe, mindful ...
(Date:7/7/2015)... ... July 07, 2015 , ... Dermatologists ... Aspen Ideas Festival (AIF), identifying 18 possible melanomas and 46 potential non-melanoma skin ... with additional testing. , The Aspen Ideas Festival, which was held from June ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... two firms have merged to form Camber Collective. Camber Collective provides strategic ... merger combines SwitchPoint’s strategy consulting expertise with Hope Consulting’s deep experience in ...
(Date:7/7/2015)... IL (PRWEB) , ... July 07, 2015 , ... ... the only industry group whose board is limited to permit holders. The Medical ... on how to move the industry forward and are committed to making sure ...
(Date:7/7/2015)... ... ... Summer is a great time to get outside and be active. It’s important ... , Jean Tapley, senior wellness coordinator at Amica, suggests the following seven tips for ... slowly. Going from no activity to several hours of activity can potentially be harmful. ...
Breaking Medicine News(10 mins):Health News:WiseWear Unveils Luxury Smart Jewelry Line 2Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 2Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 3Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 4Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Amica Insurance Has 7 Summer Safety Tips 2
... medical system, researchers find , MONDAY, Sept. 28 ... system with alerts cannot guarantee that patients will ... up signs of trouble, new research suggests. ... record that facilitates transmission and availability of critical ...
... , MONDAY, Sept. 28 (HealthDay News) -- Most men are ... two new studies find. , Although PSA tests can detect ... which are so slow-growing that they don,t need to be ... such as impotence and incontinence, and only a tiny increase ...
... ANN ARBOR, Mich.---The Great Depression had a silver lining: During ... years, according to a University of Michigan study published in ... Academy of Sciences . Life expectancy rose from 57.1 ... analysis by ,U-M researchers Jos A. Tapia Granados and Ana ...
... largest single-institution study of its kind has found few ... surgery to remove the prostate. Men in this study ... surgery indicated their cancer had recurred. ... Florida and Minnesota suggest that patients and their physicians ...
... Va. -- The Virginia Tech College of Engineering,s Robotics ... for its updated innovative robotic hand that can automatically ... team of five undergraduate students won First Place in ... and Robot Design Competition at the International Design Engineering ...
... be serious, study finds , MONDAY, Sept. 28 (HealthDay ... skin lesions that are harmless in most cases but ... a new study suggests. , Researchers examined 320 people ... Of those, 7.5 percent developed skin lesions as a ...
Cached Medicine News:Health News:Docs Miss Test Results -- Even With Alerts 2Health News:Men Not Being Told Enough About PSA Tests 2Health News:Men Not Being Told Enough About PSA Tests 3Health News:Men Not Being Told Enough About PSA Tests 4Health News:U-M study: Life and death during the Great Depression 2Health News:U-M study: Life and death during the Great Depression 3Health News:Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery 2Health News:Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery 3Health News:Improved robotic hand captures mechanical engineering top award 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: